Printed From:

In Insulin-naïve Adults With Type 2 Diabetes

Significant A1C reductions1

Study Design

An open-label, parallel-group, noninferiority trial of 582 insulin-naïve men and women with type 2 diabetes. Patients were randomized 1:1 to receive Lantus® (n=291) or detemir (n=291) once daily (in the evening) as add-on therapy to oral glucose-lowering drugs. Both insulins were titrated to FPG target of ≤108 mg/dL. An additional morning dose of detemir was allowed if predinner plasma glucose was >126 mg/dL after achievement of fasting plasma glucose of <126 mg/dL or nocturnal hypoglycemia precluded achievement of FPG target. Participants were eligible if A1C ranged from 7.5% to 10%. Primary endpoint was change in A1C at end of treatment period.

From Rosenstock.1

  • A1C decreased by 1.5% with both insulins and was comparable after 52 weeks (7.1% for Lantus® and 7.2% for detemir, respectively)
  • Overall, 52% of participants achieved A1C ≤7%; 33% (detemir) and 35% (Lantus®) without hypoglycemia

100% of Lantus® patients dosed QD throughout the study

  • Mean daily dose after 52 weeks (U/kg): detemir twice daily 1.00, detemir once daily 0.52, Lantus® 0.44
  • Incidence of major hypoglycemia: Lantus® 3%, detemir 2%
  • Overall rate of hypoglycemia (events per patient-year): 6.2 Lantus®, 5.8 detemir; P=NS

Safety Results

  • Individuals treated with BID detemir had weight gain similar to those treated with QD Lantus®


  1. Rosenstock J, Davies M, Home PD, et al. Diabetologia. 2008;51:408-416.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. August 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. August 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.